Siren LLC’s Monopar Therapeutics MNPR Stock Holding History

Siren LLC’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25M	Hold	270,118	–	–	0.51%	50
2026 Q1	$14.8M	Buy	270,118 +57,820	+27%	+$3.49M	0.41%	53
2025 Q4	$13.9M	Buy	+212,298	New	+$17.3M	0.41%	45

Other funds holding MNPR

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Siren LLC's MNPR Position: Q2 2026 in Review

Siren LLC held its Monopar Therapeutics (MNPR) position steady in Q2 2026 at 270,118 shares worth $25M. The position accounts for 0.51% of the portfolio, ranked #50.

Siren LLC first reported a position in MNPR in Q4 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

Siren LLC held 270,118 shares of Monopar Therapeutics worth $25M as of Q2 2026.
Siren LLC left its Monopar Therapeutics share count unchanged in Q2 2026.
Monopar Therapeutics made up 0.51% of Siren LLC's portfolio in Q2 2026, its #50 holding.
Siren LLC first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 3 quarters since.
96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.